臨床泌尿器科72巻7号

2018年06月発行

特集 エキスパートが本音で語る! 膀胱癌診療の最前線 〈膀胱癌治療の最前線〉

筋層浸潤性膀胱癌に対する膀胱温存療法

著者： 古賀文隆¹

所属機関： ¹がん・感染症センター都立駒込病院腎泌尿器外科

ページ範囲：P.548 - P.552

▶ポイント

・膀胱温存療法は，膀胱全摘適合症例に対する選択的膀胱温存と，膀胱全摘不適合症例に対する補完的根治治療としての膀胱温存に大別される．

・適切な適応基準とプロトコールで行われる膀胱温存療法の生命予後は膀胱全摘と同等と報告される．

・膀胱温存療法の普及を妨げる要因の1つは，膀胱全摘とのランダム化試験の欠如である．ランダム化試験は実現困難であるため良質なコホートを用いた比較研究の蓄積が必要と思われる．

参考文献

1） Coen JJ, Paly JJ, Niemierko A, et al : Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 86 : 311─316, 2013

2） Takaoka EI, Miyazaki J, Ishikawa H, et al : Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer. Jpn J Clin Oncol 47 : 67─73, 2017

3） Azuma H, Inamoto T, Takahara K, et al : Novel bladder preservation therapy with Osaka Medical College regimen. J Urol 193 : 443─450, 2015

4） Koga F, Kihara K, Yoshida S, et al : Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer : oncological outcomes of the initial 46 patients. BJU Int 109 : 860─866, 2012

5） Hara T, Nishijima J, Miyachika Y, et al : Primary cT2 bladder cancer : a good candidate for radiotherapy combined with cisplatin for bladder preservation. Jpn J Clin Oncol 41 : 902─907, 2011

6） Ritch CR, Balise R, Prakash NS, et al : Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int 121 : 745─751, 2018

7） Cahn DB, Handorf EA, Ghiraldi EM, et al : Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer 123 : 4337─4345, 2017

8） Kulkarni GS, Hermanns T, Wei Y, et al : Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol 35 : 2299─2305, 2017

9） Koga F and Kihara K : Selective bladder preservation with curative intent for muscle-invasive bladder cancer : a contemporary review. Int J Urol 19 : 388─401, 2012

10） Tunio MA, Hashmi A, Qayyum A, et al : Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer : single-institution experience. Int J Radiat Oncol Biol Phys 82 : e457─462, 2012

11） Weiss C, Wittlinger M, Engehausen DG, et al : Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70 : 1502─1506, 2008

12） Efstathiou JA, Spiegel DY, Shipley WU, et al : Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer : the MGH experience. Eur Urol 61 : 705─711, 2012

13） Huddart RA, Hall E, Lewis R, et al : Life and death of spare （selective bladder preservation against radical excision） : reflections on why the spare trial closed. BJU Int 106 : 753─755, 2010

14） Inoue M, Koga F, Yoshida S, et al : Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach. Int J Radiat Oncol Biol Phys 90 : 303─311, 2014

15） Kawashima A, Nakayama M, Kakuta Y, et al : Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 17 : 2561─2569, 2011

16） Yoshida S, Koga F, Kobayashi S, et al : Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 83 : e21─27, 2012